Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 89c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $239.15 -0.38%
EPS Growth %: -20.5%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
SUNB, CULP, KFY, More
EPS Growth %: -20.5%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
SUNB, CULP, KFY, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $4.20, $0.89 better than the analyst estimate of $3.31. Revenue for the quarter came in at $838.1 million versus the consensus estimate of $832.52 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- BridgeBio Oncology Therapeutics, In (BBOT) PT Lowered to $15 at Stifel
- BMO cautious on softlines, bearish on athletic names
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
